Corvus Pharmaceuticals, Inc. (CRVS) income statement
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.67−0.34 (-3.40%)
Close on Nov 20, 2026Market cap $813.45MP/E –Yield –
Corvus Pharmaceuticals, Inc. financial ratios
See a number that looks wrong?